Clusters of seizures, prolonged seizures, and status epilepticus occur more frequently in children with multiple disabilities, and chronic seizures are more likely to be refractory to treatment. In many patients, the seizures appear to contribute to the mental retardation. Thus, if the lives of these children are to improve, seizure control is essential. However, medical treatment can interfere with cognition and cause behavioral disturbances, making life very difficult for the child and the child's family. With the introduction of 10 new antiepileptic drugs in the last decade, the treatment of epilepsy in multiply handicapped children has significantly advanced. These new antiepileptic drugs may improve seizure control, medication tolerance, or both. Although the ultimate therapeutic goal is to keep children seizure free and alert, compromises regarding medication choice and dosage are still necessary in many cases. Novel treatment options, such as the vagus nerve stimulator, may decrease seizure frequency without behavioral or cognitive side effects. In carefully selected children with specific epilepsy syndromes, epilepsy surgery can provide partial or complete relief from seizures. (J Child Neurol 2004;19(Suppl 1):S58-S64).
Get full access to this article
View all access options for this article.
References
1.
White HS: Preclinical development of antiepileptic drugs: Past, present, and future directions. Epilepsia2003;44(Suppl 7):2-8.
2.
Pellock JM, Morton LD: Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev2000;6:309-323.
3.
Alvarez N., Besag F., Livanainen M.: Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res1998;42(Suppl 1):1-15.
4.
Mikati MA, Lepejian GA, Holmes GL: Medical treatment of patients with infantile spasms. Clin Neuropharmacol2002;25:61-70.
5.
Graniewski-Wijnands HS, van der Torren K.: Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol2002;104:189-194.
Dodson WE: Felbamate in the treatment of Lennox-Gastaut Syndrome: Results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):518-524.
13.
Acute liver failure linked to felbamate use [News]. Am J Hosp Pharm1994;51:2882, 2887.
14.
Shorvon SD: Gabapentin, in Handbook of Epilepsy Treatment. Oxford, UK, Blackwell Science Ltd, 2000, 106-108.
15.
Khurana DS, Riviello J., Helmers S., et al: Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr1996;128:829-833.
16.
Mikati MAChoueri R., Khurana DS et al: Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res1998:42(Suppl 1):57-62.
17.
Vossler DG: Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin . Neurology1996;46:852-853.
18.
Chudnow RS, Dewey RB, Lawson CR: Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Arch Neurol1997;54:910-912.
19.
Gidal BEWalker JK, Lott RS, et al: Efficacy of lamothgine in institutionalized, developmentally disabled patients with epilepsy: A retrospective evaluation. Seizure2000;9:131-136.
20.
Buchanan N.The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure1990;4:233-236.
21.
Franz DN, Tudor C., Leonard J., et al: Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia2001;42:935-940.
22.
Lardizabal DV, Morris HH, Hovinga CA, Del Mar CarrenoM: Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. Epilepsia2003;44:536-539.
23.
Ettinger AB , Weisbrot DM, Saracco J., et al: Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia1998;39:874-877.
24.
Glauser TA, Levisohn PM, Ritter F., et al: Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Epilepsia2000;41(Suppl 1):S86-S90.
25.
Guerreiro MM , Manreza MLG, Scotoni AE, et al: A pilot study of topiramate in children with Lennox-Gastaut syndrome. Arq Neuropsiquiatr1999;57:167-175.
26.
Sachdeo RC, Glauser TA, Ritter F., et al: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology1999;52:1882-1887.
27.
Glauser TA, Clark PO, McGee K.: Long-term response to topiramate in patients with West syndrome. Epilepsia2000 ;41(Suppl 1):591-S94.
28.
Nieto-Barrera, Candau R, Nieto-Jimenez , et al: Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure2000 ;9:590-594.
29.
Takeoka M., Holmes GL, Thiele E., et al: Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia2001;42:387-392.
30.
Montenegro MA, Guerreiro MM, Scotoni AE, Guerreiro CAM: Predisposition to metabolic acidosis induced by topiramate. Arq Neuropsiquiatr2000;58:1021-1024.
31.
Philippi H. , Boor R., Reitter B.Topiramate and metabolic acidosis in infants and toddlers. Epilepsia2002;43:744-747.
32.
Wilner A., Raymond K., Pollard R.: Topiramate and metabolic acidosis. Epilepsia1999;40:792-795.
33.
Areas J., Ferrer T., Roche MC, et al: Hypohidrosis related to the administration of topiramate to children. Epilepsia2001;42: 1363-1365.
34.
Gerber PE, Hamiwka L., Connolly MB, Farrell K.: Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurol2000;22:200-203.
35.
Kälviäinen R.: Tiagabine: A new therapeutic option for people with intellectual disability and partial epilepsy. J Intellect Disabil Res1998;42:63-67.
36.
Akman CI, Schubert R.: The role of tiagabine in the treatment of intractable epilepsy of childhood with multifocal independent spikes: A case report. Clin Electroencephalogr2000;31:207-210.
37.
Chmielewska B., Stelmasiak Z.: Effectiveness of adjunctive therapy with tiagabine in mentally disabled patients with epilepsy. Ann Univ Mariae Curie Sklodowska [Med]2002;57:226-236.
38.
Piccinelli P., Borgatti R., Perucca E., et al: Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria. Epilepsia2000 ;41:1485—1488.
39.
Balslev T., Uldall P.Buchhold J: Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatr Neurol2000;4:169-170.
40.
Ben-Menachem E.Gilland E: Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure2003;12:131-135.
41.
Franz DN, Tudor C., Leonard JM, et al: Levetiracetam Therapy for Epilepsy in Tuberous Sclerosis. Poster presented at the Annual Meeting of the American Epilepsy Society, Seattle, Washington, December 9, 2002.
42.
Gibson G.: Efficacy of levetiracetam in developmentally disabled patients: A review of the literature and six case reports. Epilepsy Behav2002;3:280-284.
43.
Smith MC, Hershkowitz L., Beulow JM, Zelinski D.: Zonisamide therapy in frontal lobe or progressive myoclonic epilepsy, abstract . Epilepsia2000;43:48.
44.
Bourgeois BFD : Zonisamide in the treatment of myoclonic astatic epilepsy (Doose syndrome), abstract. Epilepsia2002;43:56.
45.
Yanai S., Hanai T., Narazaki O.: Treatment of infantile spasms with zonisamide. Brain Dev1999;21:157-161.
46.
Suzuki Y., Imai K., Toribe Y., et al: Long-term response to zonisamide in patients with West syndrome . Neurology2002;58: 1556-1559.
47.
Tran TA, Leppik IE, White JR, et al. The effect of zonisamide on weight, abstract. Epilepsia2002;23(Suppl 7):211.
48.
Gaily E., Granström, LiukkonenE: Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res1998;42:41-45.
49.
Franz DN, Leonard J., Tudor CA, et al: Oxcarbazepine therapy of epilepsy in tuberous sclerosis, abstract . Epilepsia2002;43:57.
50.
Van Amelsyoort T., Bakshi R., Devaux CB, Schwabe S.: Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review. Epilepsia1994;35:181-188.
51.
Shields WD, Sankar R.: Vigabatrin. Semin Pediatr Neurol1997 ;4: 43-50.
52.
Chiron C., Dulac O., Luna D., et al: Vigabatrin in infantile spasms. Lancet1990;335:363-364.
53.
Elterman RDShields WD, Mansfield KA, et al: Randomized trial of vigabatrin in patients with infantile spasms. Neurology2001;57:1416-1421.
54.
Freeman JM, Vining EP, Pillas DJ, et al: The efficacy of the ketogenic diet-1998: A prospective evaluation of intervention in 150 children. Pediatrics1998;102:1358-1363.
55.
Kossoff EH, Pyzik PLMcGrogan JR, et al: Efficacy of the ketogenic diet for infantile spasms. Pediatrics2002; 109:780-783.
56.
Wilfong AA: Treatment considerations: Role of vagus nerve stimulator. Epilepsy Behav2002;3(Suppl 6S1): S41-S44.
57.
Hornig GW, Murphy JV, Schallert G., Tilton C.: Left vagus nerve stimulation in children with refractory epilepsy: An update . South Med J1997;90:484-488.
58.
Majoie HJM , Berfelo MW, Aldenkamp AP, et al: Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome. J Clin Neurophysiol2001 ;38:419-428.
59.
Maehara T., Shimizu H.: Surgical outcome of corpus callosotomy in patients with drop attacks . Epilepsia2001;42:67-71.
60.
Mathern GW, Giza CC, Yudovin S., et al: Postoperative seizure control and antiepileptic drug use in pediatric epilepsy surgery patients: The UCLA experience, 1986-1997. Epilepsia1999; 40:1740-1749.
61.
Shields WD: Medical versus surgical treatment: Which treatment when?Int Rev Neurobiol2002;49:253-267.
